The analysis revealed that CSF cfDNA methylation profiles exhibit distinct patterns that differentiate IDH-mutant from IDH-wildtype tumors and gliomas from controls, establishing their potential as diagnostic biomarkers. The gene discussed is IDH2; the disease is central nervous system cancer.